A community-marketed three-peptide blend — BPC-157 + TB-500 + GHK-Cu. Sold as a single vial; the combination has no published human evidence and is component-extrapolated throughout.
No published clinical trial — RCT, pilot, case series, or observational study — exists for the GLOW combination in any species. Every claim about GLOW's effects below is extrapolated from individual-component preclinical literature. The three peptides have not been studied together in humans, and there is no published PK, stability, or compatibility data for the blend itself.
GLOW is a pre-mixed blend of three peptides: BPC-157, TB-500, and GHK-Cu. Sold as a single vial for convenience, it combines the "Wolverine stack" (BPC + TB) plus the copper peptide's skin/hair effects into one injection.
The name reflects its primary use case: skin, hair, and aesthetic anti-aging. The components each have a separate community-use case (BPC-157 for soft-tissue recovery, TB-500 for systemic regeneration, GHK-Cu for skin) — none is FDA-approved for any indication.
Components not individually FDA approved; the GLOW combination has no IND/NDA. WADA: BPC-157 prohibited under S0 (Non-Approved Substances); TB-500 prohibited under S2.3 (Growth Factors and Growth Factor Modulators). GHK-Cu is sold as a topical cosmetic ingredient (INCI: Copper Tripeptide-1) under CIR 2014/2018 "safe as used" coverage; injectable use is not FDA-approved. In April 2026 FDA procedurally removed all three from compounding Category 2 because original nominators withdrew — this is not safety clearance and does not authorize compounding. PCAC will review BPC-157 and TB-500 on July 23, 2026 and GHK-Cu in February 2027 for §503A bulks-list inclusion. None is legally compoundable today. DoD/OPSS specifically warns service members against BPC-157 and any blend containing it.
Angiogenesis, fibroblast activation, and growth-hormone receptor upregulation — creates the foundation for skin and tissue repair.
TB-500 is a synthetic heptapeptide (Ac-LKKTETQ, residues 17–23 of full-length thymosin β4) that retains the actin-sequestering motif. Full-length Tβ4 has rodent evidence for cell migration, wound healing (Malinda 1999, PMID 10469335), and hair-follicle development (Philp 2004, PMID 15037013) — but the 7-aa fragment's reproduction of these broader effects has not been formally demonstrated. The hair-regrowth and systemic-regeneration framing borrows full-Tβ4 evidence; for the heptapeptide, evidence is mechanistic plausibility plus community use.
GHK-Cu is a copper-shuttle tripeptide (log K₁ ≈ 16.44 for Cu(II), Pickart 2008 PMID 18644225) that supplies copper as a cofactor for lysyl oxidase (collagen crosslinking) and Cu/Zn-SOD. In cultured human fibroblasts at supraphysiologic concentration, GHK altered expression of ~31% of Connectivity-Map-assayed genes (~4,000 of ~12,800), shifting expression toward patterns characteristic of younger cells (Pickart & Margolina 2018, PMID 29986520) — in vitro fibroblast finding, not in-vivo whole-organism gene regulation. Topical clinical evidence (Leyden 2002, Finkey 2005) supports modest skin metric improvements over 8–12 weeks; injectable-route human evidence does not exist.
Three components target three mechanistically non-overlapping pathways — local healing (BPC-157), cell migration (TB-500 / Tβ4 actin sequestration), and copper-cofactor + gene-expression modulation (GHK-Cu). Whether these combine additively, synergistically, or with cross-interference has not been measured; the 8–12 week visible-improvement timeline is borrowed from the GHK-Cu topical literature (Leyden 2002, 8–12 wk RCT duration), not validated for the injectable blend.
| Benefit | Evidence |
|---|---|
| Skin firmness & elasticity | GHK-Cu clinical studies: measurable improvements over 12 weeks |
| Fine lines & wrinkles | Reduction via collagen upregulation; visible by 8–12 weeks |
| Skin tone / brightness | GHK-Cu reduces hyperpigmentation; TB-500 supports skin cell turnover |
| Hair regrowth | Combined TB-500 (follicle stem cells) + GHK-Cu (follicle enlargement, anagen extension) |
| Wound & scar healing | All three components individually documented |
| General recovery | BPC + TB provide meaningful soft-tissue recovery as a side benefit |
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeSame SubQ dosing for systemic support, plus dermarolling 1–2×/week on the scalp with a GHK-Cu topical solution. Combined with oral finasteride or minoxidil for synergy.
GLOW is typically supplied as a pre-mixed blend of 10 mg BPC-157 + 10 mg TB-500 + 50 mg GHK-Cu (70 mg total) in a single vial. Exact ratios vary by supplier — check your label. The blue color indicates the copper.
Blend (10 mg BPC-157 + 10 mg TB-500 + 50 mg GHK-Cu = 70 mg total) + 2 mL BAC water = 35 mg/mL total peptide. At this concentration: BPC-157 5 mg/mL, TB-500 5 mg/mL, GHK-Cu 25 mg/mL.
| Target dose (BPC) | Other components | Volume | Syringe Units |
|---|---|---|---|
| 250 mcg BPC-157 | 250 mcg TB + 1.25 mg GHK-Cu | 0.05 mL | 5 units |
| 500 mcg BPC-157 | 500 mcg TB + 2.5 mg GHK-Cu | 0.10 mL | 10 units |
| 750 mcg BPC-157 | 750 mcg TB + 3.75 mg GHK-Cu | 0.15 mL | 15 units |
Check your specific vial's component ratios — they vary. Match your dose to the BPC-157 target; the other two scale with it proportionally. Confirm against your specific vial's label — supplier ratios vary, and the dose at a given draw volume is only correct for the 10/10/50 ratio.
All compounds share one vial. Edit any amount or change the BPC-157 dose — the other doses scale by ratio.
Insulin syringe — 100 units = 1 mL
Free account. Saves your reconstitution + schedules doses + tracks every vial.
Dosing cheat sheet, reconstitution reference, and cycle planning — delivered to your inbox.
Adverse-effect profile is inferred from individual-component literature; no published safety data exists for the GLOW combination. Long-term safety of repeated injectable copper loading from chronic GHK-Cu use has not been formally characterized; periodic ceruloplasmin / serum copper / 24-h urinary copper monitoring is reasonable for users on extended high-dose regimens.
Looking for GLOW (BPC-157 + TB-500 + GHK-Cu)? We recommend NextGen Peptides — third-party tested, fast shipping, and trusted by the StackTrax community.
10% off with code
Exclusive StackTrax discount
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeGLOW is a pre-mixed blend of three peptides: BPC-157, TB-500, and GHK-Cu. It is sold as a single vial that combines the so-called Wolverine stack (BPC + TB) with the copper peptide's skin and hair effects. The name reflects its primary use case for skin, hair, and aesthetic anti-aging. None of the three components is individually FDA approved and the combination has no IND or NDA.
No. No published clinical trial (RCT, pilot, case series, or observational study) exists for the GLOW combination in any species. Every claim about GLOW's effects is extrapolated from individual-component preclinical literature. There is no published PK, stability, or compatibility data for the three-peptide blend itself, and the 8 to 12 week visible-improvement timeline is borrowed from GHK-Cu topical studies, not validated for the injectable blend.
Each component targets a mechanistically non-overlapping pathway: BPC-157 drives local healing via angiogenesis and fibroblast activation, TB-500 (a heptapeptide fragment of thymosin beta-4) contributes actin sequestration and cell migration signaling, and GHK-Cu is a copper-shuttle tripeptide that supplies copper as a cofactor for lysyl oxidase and Cu/Zn-SOD. Whether these combine additively, synergistically, or with cross-interference has not been measured in any peer-reviewed study.
Community protocol is one injection per session, 3 to 5 times per week SubQ in the abdomen, run as 8 to 12 week cycles with 2 to 4 week breaks. A typical vial contains 10 mg BPC-157 + 10 mg TB-500 + 50 mg GHK-Cu (70 mg total) reconstituted in 2 mL bacteriostatic water. At that concentration a 0.05 to 0.15 mL draw delivers roughly 250 to 750 mcg of BPC-157 and TB-500 plus 1.25 to 3.75 mg GHK-Cu. Supplier ratios vary, so confirm against your specific vial's label.
KLOW is GLOW with KPV added as a fourth component. The three-peptide GLOW base (BPC-157, TB-500, GHK-Cu) handles angiogenesis, cell migration, and collagen synthesis. KLOW adds KPV as a community-marketed NF-kB pathway modulator to lean the blend toward inflammatory skin conditions like eczema, psoriasis, and rosacea. GLOW is positioned more for general skin, hair, and aesthetic anti-aging.
Common effects are injection site reactions (a blue tint from copper fades within minutes), mild fatigue early in use, and transient pigmentation at the injection site from GHK-Cu. GLOW is contraindicated with Wilson's disease, active hepatic copper overload, patients on copper-chelating medications (penicillamine, trientine), active malignancy, and pregnancy or breastfeeding. The full safety profile is inferred from individual-component literature since no combination safety data exists. Long-term injectable copper loading from chronic GHK-Cu use has not been formally characterized.
Components are not individually FDA approved. WADA prohibits BPC-157 under S0 (Non-Approved Substances) and TB-500 under S2.3 (Growth Factors and Growth Factor Modulators) at all times, with no TUE pathway, so GLOW is prohibited for athletes via those components. GHK-Cu is sold as a topical cosmetic ingredient (INCI: Copper Tripeptide-1) but injectable use is not FDA approved. In April 2026 FDA procedurally removed all three from compounding Category 2 because original nominators withdrew, which is not safety clearance and does not authorize compounding. DoD/OPSS specifically warns service members against BPC-157 and any blend containing it.
Disclaimer: This guide is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The compounds discussed are not FDA approved for human use. Always consult a qualified healthcare provider before starting any new supplement or peptide protocol. StackTrax does not sell peptides or supplements directly — purchase links go to third-party vendors. StackTrax is not responsible for the products, quality, or business practices of any third-party vendor. This page contains affiliate links — StackTrax may earn a commission on purchases at no extra cost to you.
© 2026 StackTrax, LLC. All rights reserved.
StackTrax guides cover peptides and compounds that are not FDA-approved for the uses discussed. The dosing, reconstitution, and safety information is compiled from published research and community protocols for educational purposes only.
Before using any compound mentioned here, consult a qualified healthcare provider. StackTrax does not sell, prescribe, or recommend these substances for personal use.
These pages also contain affiliate links. We may earn a commission on purchases at no extra cost to you — this never changes our editorial recommendations.